Tune Therapeutics' new method of CRISPR-based gene editing shows promise in curtailing chronic hepatitis B infections.
June 1, 2026 02:48 PM EDT
R&DCell/Gene Tx
Epigenetic editing shows promise against chronic hep B infections
Ryan Cross
Senior Science Correspondent
Tune Therapeutics Presents Positive Phase 1b/2a Proof of Concept Data on TUNE-401: a First-in-Class Epigenetic Silencer for…
Across two large trials, roughly 20% of people treated with bepirovirsen had undetectable levels of the virus after stopping all…
Early last year, startup iECURE’s experimental gene therapy seemingly cured a baby of a life-threatening genetic disease. But new…
Epicrispr reports early cut data showing lean muscle gains on its FSHD epigenetic editing therapy EPI-321, using AI
Scientists developed a new CRISPR technology that targets specific RNA molecules. This breakthrough allows for the selective…
New research suggests a first-of-its-kind drug for hepatitis B may let some patients stop treatment without showing signs of the…
